NCT00934180View on ClinicalTrials.gov

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
Healthy
Interventions
DRUG

Ondansetron

1 x 8 mg Orally Disintegrating Tablet

DRUG

Zofran®

1 x 8 mg ODT

Trial Locations (1)

77042

Novum Pharmaceutical Research Services, Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00934180 - Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter